Previously, we observed that higher expression of Nodal correlated with advanced stage disease and resistance to therapy -- in the context of BRAFi therapy in melanoma patients [15] and independently in breast cancer patients receiving standard-of-care therapy [13]. Here, NODAL is linked to breast cancer.